FY2024 EPS Estimates for Ascendis Pharma A/S (NASDAQ:ASND) Increased by Analyst

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Ascendis Pharma A/S in a research report issued on Monday, September 16th. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will post earnings per share of ($6.54) for the year, up from their previous estimate of ($6.59). Cantor Fitzgerald currently has a "Overweight" rating and a $170.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($6.83) per share.

Several other equities analysts have also commented on ASND. Oppenheimer restated an "outperform" rating and set a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday. Citigroup upped their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a research report on Tuesday. Stifel Nicolaus initiated coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They set a "buy" rating and a $200.00 price target on the stock. TD Cowen reduced their price objective on Ascendis Pharma A/S from $175.00 to $157.00 and set a "buy" rating for the company in a research report on Wednesday, September 4th. Finally, Jefferies Financial Group raised their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research report on Tuesday, August 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $193.77.

Ascendis Pharma A/S Stock Up 1.6 %

NASDAQ ASND traded up $2.29 during trading hours on Wednesday, hitting $148.88. The company had a trading volume of 885,105 shares, compared to its average volume of 438,193. The firm has a market cap of $8.67 billion, a P/E ratio of -15.22 and a beta of 0.63. Ascendis Pharma A/S has a fifty-two week low of $85.29 and a fifty-two week high of $161.00. The business has a fifty day simple moving average of $132.71 and a 200-day simple moving average of $136.43.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently modified their holdings of ASND. Gilbert & Cook Inc. grew its holdings in Ascendis Pharma A/S by 8.4% during the fourth quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company's stock worth $357,000 after acquiring an additional 220 shares during the period. Quadrant Capital Group LLC grew its stake in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 151 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 1.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company's stock worth $2,064,000 after purchasing an additional 159 shares in the last quarter. Trexquant Investment LP acquired a new stake in Ascendis Pharma A/S during the fourth quarter valued at approximately $1,243,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after buying an additional 91 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.